Moreover, after the recent demonstration of efficacy of the anti-HER2 agent trastuzumab in the treatment of HER-2 positive advanced gastric cancer (Bang et al. 2010), the combination of trastuzumab with a chemotherapy doublet (cisplatin with a fluoropyrimidine) represents the treatment of choice in this subset of patients. The gene discussed is ERBB2; the disease is gastric cancer.